Advaxis Reports Preclinical Study of LM-LLO Immunotherapy Showed Tumor Eradication

By: via Benzinga
Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company developing cancer immunotherapies, announced the publication of preclinical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.